News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
262,160 Results
Type
Article (13962)
Company Profile (304)
Press Release (247894)
Section
Business (79437)
Career Advice (152)
Deals (13201)
Drug Delivery (35)
Drug Development (50345)
Employer Resources (31)
FDA (5689)
Job Trends (5121)
News (144244)
Policy (10023)
Tag
Academia (901)
Alliances (21545)
Alzheimer's disease (762)
Approvals (5674)
Artificial intelligence (70)
Bankruptcy (101)
Best Places to Work (4524)
Biotechnology (249)
Breast cancer (110)
Cancer (908)
Cardiovascular disease (71)
Career advice (132)
CAR-T (76)
Cell therapy (220)
Clinical research (40173)
Collaboration (315)
Compensation (134)
COVID-19 (1007)
C-suite (79)
Cystic fibrosis (67)
Data (987)
Diabetes (87)
Diagnostics (1208)
Drug discovery (57)
Earnings (29042)
Events (47247)
Executive appointments (253)
FDA (6069)
Funding (312)
Gene editing (64)
Gene therapy (166)
GLP-1 (311)
Government (1065)
Healthcare (6551)
Infectious disease (1045)
Inflammatory bowel disease (98)
IPO (7201)
Job creations (860)
Job search strategy (127)
Layoffs (190)
Legal (1376)
Lung cancer (134)
Lymphoma (63)
Manufacturing (88)
Medical device (2561)
Medtech (2562)
Mergers & acquisitions (6144)
Metabolic disorders (262)
Neuroscience (1009)
NextGen Class of 2024 (2011)
Non-profit (851)
Northern California (1110)
Obesity (142)
Opinion (91)
Parkinson's disease (78)
Patents (63)
People (25135)
Phase I (14166)
Phase II (18677)
Phase III (11828)
Pipeline (369)
Postmarket research (851)
Preclinical (5972)
Radiopharmaceuticals (206)
Rare diseases (205)
Real estate (1413)
Regulatory (8303)
Research institute (931)
Southern California (989)
Startups (1964)
United States (8790)
Vaccines (165)
Weight loss (84)
Date
Last 7 days (93)
Last 30 days (987)
Last 365 days (20125)
2025 (53)
2024 (20596)
2023 (22418)
2022 (26826)
2021 (27813)
2020 (23372)
2019 (16243)
2018 (11749)
2017 (13752)
2016 (11849)
2015 (14353)
2014 (10397)
2013 (7490)
2012 (7541)
2011 (7621)
2010 (7456)
Location
Africa (147)
Asia (16972)
Australia (2861)
California (2511)
Canada (825)
China (216)
Colorado (93)
Connecticut (106)
Europe (36480)
Florida (277)
Georgia (71)
Illinois (156)
Indiana (62)
Maryland (338)
Massachusetts (1973)
Michigan (58)
Minnesota (102)
New Jersey (643)
New York (696)
North Carolina (422)
Northern California (1110)
Ohio (84)
Pennsylvania (483)
South America (207)
Southern California (989)
Texas (285)
Washington State (252)
262,160 Results for "tlc therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR
TLC BioSciences announced that the Abstract Selection Committee of the American College of Rheumatology has accepted TLC’s late-breaking abstract on TLC599 for oral presentation at ACR Convergence 2023.
November 8, 2023
·
4 min read
Biotech Bay
OrsoBio to Present Phase 1 and Preclinical Data for Liver-Targeted Mitochondrial Protonophore TLC-6740 at the American Diabetes Association’s 84th Scientific Sessions
OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, today announced new data for liver-targeted mitochondrial protonophore TLC-6740 being presented at the 84th Scientific Sessions of the American Diabetes Association being held June 21-24, 2024, in Orlando, Fla.
June 21, 2024
·
6 min read
Biotech Bay
TLC to Present at the 42nd Annual JP Morgan Healthcare Conference
TLC BioSciences announced that the company will present at the 42nd Annual JP Morgan Healthcare Conference at 2:00pm PT on Tuesday, January 9, 2024.
December 27, 2023
·
1 min read
Press Releases
Tonix Pharmaceuticals Announces Participation in Endpoints Panel at the Long COVID Workshop and RECOVER TLC Workshop Convened by the Foundation for the National Institutes of Health (FNIH) and the National Institute of Allergy and Infectious Diseases (NIAID)
October 1, 2024
·
6 min read
Drug Development
OrsoBio to Present Phase 1 Data for the Liver-Targeted Mitochondrial Protonophore TLC-6740 in Development for the Treatment of Obesity at ObesityWeek® 2023
OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced preliminary safety and pharmacokinetic (PK) data from the single ascending dose (SAD) portion of an ongoing Phase 1 trial of TLC-6740, a liver-targeted, mitochondrial protonophore.
October 16, 2023
·
5 min read
Drug Development
OrsoBio Announces Phase 1 Trial of TLC-6740, a Mitochondrial Protonophore for the Treatment of Obesity and Associated Diseases
OrsoBio, Inc. today announced completion of the second cohort of subjects in an ongoing Phase 1 trial of TLC-6740, a liver-targeted mitochondrial protonophore.
June 5, 2023
·
4 min read
Business
TLC Announces TLC599 Agreement with EndoOne of the largest deals seen in Taiwan’s biotech sector
TLC BioSciences announced that it has entered a commercialization agreement with Endo International plc for rights in the United States to TLC599, a proprietary BioSeizer® sustained release injectable in Phase 3 development for the treatment of osteoarthritis pain.
June 13, 2022
·
5 min read
Drug Development
OrsoBio Announces First Patient Dosed in Phase 2 Clinical Trial of the ACC2 Inhibitor TLC-3595, a Potential Treatment for Type 2 Diabetes
OrsoBio, Inc. today announced that the first patient has been dosed in a Phase 2a clinical trial evaluating TLC-3595, a selective inhibitor of acetyl-CoA carboxylase 2 (ACC2).
March 20, 2023
·
4 min read
Biotech Bay
OrsoBio Initiates IND-Enabling Activities for Liver-Targeted Mitochondrial Protonophore TLC-6740 for the Treatment of Severe Metabolic Disorders
OrsoBio Initiates IND-Enabling Activities for Liver-Targeted Mitochondrial Protonophore TLC-6740 for the Treatment of Severe Metabolic Disorders.
November 2, 2022
·
4 min read
Drug Development
TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy
TLC BioSciences, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced that detailed results of its TLC599 Phase 2 clinical trial in patients with osteoarthritis of the knee have been published in the peer-reviewed journal Arthritis Research & Therapy.
March 7, 2022
·
3 min read
1 of 26,216
Next
